Structure Therapeutics (GPCR) CSO has 18,735 shares withheld for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Structure Therapeutics Inc. chief scientific officer Xichen Lin reported a routine tax-related share transaction. On March 3, 2026, Lin had 18,735 Ordinary Shares withheld at $20.99 per share to cover income taxes triggered by the vesting of a restricted share unit award.
After this tax-withholding disposition, Lin directly owned 185,592 Ordinary Shares. The company notes that each American Depositary Share (ADS) represents three Ordinary Shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Lin Xichen
Role
CHIEF SCIENTIFIC OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Ordinary Shares | 18,735 | $20.99 | $393K |
Holdings After Transaction:
Ordinary Shares — 185,592 shares (Direct)
Footnotes (1)
- The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
FAQ
What insider transaction did Structure Therapeutics (GPCR) report for Xichen Lin?
Structure Therapeutics reported that chief scientific officer Xichen Lin had shares withheld to cover taxes. On March 3, 2026, the company withheld 18,735 Ordinary Shares as part of income tax obligations tied to the vesting of a restricted share unit award.
Was the GPCR Form 4 transaction a sale by Xichen Lin on the open market?
The Form 4 describes a tax-withholding disposition, not an open-market sale. 18,735 Ordinary Shares were withheld by the issuer to satisfy income tax obligations upon RSU vesting, rather than being sold at the officer’s discretion in the market.
What does transaction code F mean in the Structure Therapeutics Form 4?
Transaction code F indicates payment of an exercise price or tax liability by delivering securities. In this case, 18,735 Ordinary Shares were withheld by Structure Therapeutics to satisfy chief scientific officer Xichen Lin’s income tax obligations from a restricted share unit vesting.